DeepSyte™
Bill FeedAll repsScoreboardsPrimariesProAboutSign inGet started
DeepSyte™™

A nonpartisan civic accountability tool. We match federal legislation to your stated values — without partisan bias.

Learn

  • About
  • About the name
  • Methodology
  • Glossary

Legal

  • Privacy
  • Terms of Service
  • Refund Policy
  • Contact

Sources

Bill data from Congress.gov. Summaries from the Congressional Research Service where available.

Follow

  • Bluesky — @deepsyte.app
  • X — @deepsyteapp
All content is for informational purposes only. Always verify against primary sources.
Back to bill feed
118-hr-7384Committee
Sign in to get alerts

Creating Hope Reauthorization Act of 2024

Read the record. Not the rhetoric.

See how your representatives voted on this bill.

DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.

Get started freeTake the values quiz

Alignment with your views

Sign in and take the values quiz to see how this bill lines up with what you've said.

Summary

Official CRS summary

This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)

Read full bill text

Values analysis

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.

Bill details

Congress
118
Bill type
hr
Introduced
February 15, 2024
Sponsor
Not yet available
Last action
February 16, 2024— Referred to the Subcommittee on Health.

How your representatives voted

Sign in to see how your representatives voted on this bill.